Nabriva Therapeutics PLC at Bank of America Merrill Lynch Health Care Conference Transcript
Thank you, everybody. We're going to get moving here in the afternoon with our next company presenter. My name's Jason Gerberry. I'm the U.S. pharma analyst at Bank of America. I'm pleased to be introducing Nabriva and CEO, Ted Schroeder. So Ted, thanks for joining us at the conference.
Hey, thanks for having us, Jason. Always appreciate it.
So maybe I'm not sure if you want to provide any introductory remarks as it pertains to Nabriva and helping investors think about how Nabriva takes a differentiated approach to the anti-infective space.
Yes, sure. Thanks. So I think what's different about Nabriva is that we have 2 compounds that are in front of the FDA. So
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
